I am posting this knowing it may end my standing with the Royal College, and I am posting it anyway. Because two days ago a patient of mine handed me a notebook with the words I AM DONE written on every page, in different pens, on twenty-three different days, and I cannot keep my mouth shut. I'm Dr Marcus Hartwell. I'm a clinical neurologist with nineteen years in practice. The last seven of those years I have spent at the Headache Mechanism Research Institute. I trained at Edinburgh. I have referred hundreds of women for Botox, Aimovig, Ajovy and Emgality. I have written the prescriptions. I have signed the forms. And about three years ago I worked out that my profession is doing this wrong. By the time you finish reading this, you should be FURIOUS. If you have ever tried magnesium for migraines, taken it for three or four weeks, given up, and quietly concluded that magnesium "doesn't work for me", keep reading. You were never told the three mistakes nobody in my profession bothers to explain to women. Let me tell you about Patricia. A HEAD TEACHER WALKED IN AT 2:31 ON A WEDNESDAY AFTERNOON. Patricia. 49. Head teacher at a primary school in Leeds. Mother of three. Married 24 years. Twelve attack days a month for three years. She put a leather notebook on my desk. She said, very quietly: "READ IT. JUST READ IT." I opened the notebook. Twenty-three pages. Different inks, different dates. Each page said the same thing in different versions: "I AM DONE. I am done. I AM DONE." She had been on amitriptyline, gained eleven pounds. On propranolol, fainted twice. On topiramate, her words: "I FORGOT MY HUSBAND'S NEPHEW'S NAME AT HIS OWN CHRISTENING. I just stood there. I knew his face. I couldn't find his name." Quit topiramate after fourteen weeks. On Botox: £1,800 a session, three rounds, partial relief, brow drop she had to hide with a fringe. She had been offered Aimovig and she had said no because her sister-in-law had been on it for nine months and gained twenty-six pounds, lost a third of her hair, and developed dysautonomia. She had tried magnesium, twice. Once a Boots magnesium oxide. Once a Calm powder. Six weeks total, across both attempts. Concluded: "Magnesium doesn't work for me." Total spend on her migraines across five years: £18,400. She said: "Doctor, I am running out of jobs to apologise to. I have written the letter to the governors three times this term and not sent it. Just tell me if there is a NEXT THING." I sent her home with a prescription she didn't fill and a coffee I made her in the staff room. And I went home that night and read until five in the morning. WHAT I FOUND CHANGED HOW I PRACTISE. The MAUSKOP TRIAL, Headache, 1996. SUNY Downstate. Intravenous magnesium sulphate in acute migraine. 80% of patients experienced complete pain elimination within fifteen minutes. Here's the counter-evidence stat that should have made the BMJ front page. The patients whose ionised magnesium was low, measured properly, not by the standard serum panel, had 86% sustained relief at 24 hours. The patients whose standard blood test had read "normal" had only 16% sustained relief. The standard blood test had MISSED the deficit in half of the acute attack patients in that trial. The American Migraine Foundation publishes this on their resource page: standard serum magnesium levels measure roughly 2% of total body magnesium and do not reflect brain stores. YOUR GP DID NOT LIE TO YOU. She measured exactly what she was trained to measure. Which was the wrong 2%. Adams 2015, Journal of Biomedical Education: 71% of medical schools fail to provide the recommended minimum 25 hours of nutrition education in a four-year curriculum. The AVERAGE is 19 hours. Across four years. To prepare your GP for the entire metabolic side of medicine. That is not a conspiracy. That is a curriculum gap. Then I went into the prophylaxis literature. PEIKERT 1996 USED CITRATE. PFAFFENRATH 1996 USED ASPARTATE. SAME YEAR. OPPOSITE RESULT. Peikert: 81 patients, trimagnesium dicitrate 600mg/day, twelve weeks, 41.6% reduction in attack frequency vs 15.8% placebo. Pfaffenrath: a different magnesium salt, nearly half the treatment group dropped out with diarrhoea, no benefit. The variable was never the molecule. The variable was the form, the dose, and the duration. NOW HERE IS WHAT NOBODY HAS LAID OUT FOR YOU. Think of your brain as a door with three locks. TOP LOCK. The NMDA receptor. The door that lets cortical spreading depression (the wave of electrical activity that starts a migraine) get going. Magnesium is the natural ion that blocks it. MIDDLE LOCK. Nerve excitability. How easily your trigeminal system fires off into pain. BOTTOM LOCK. The mitochondria. The power plants in every neuron. Lodi 2001, University of Bologna: magnetic resonance spectroscopy showed cytosolic free magnesium and ATP hydrolysis energy were both reduced in the occipital lobes of migraine patients. Direct imaging. Not theory. They saw the power supply running low. In the migraine brain ALL THREE LOCKS ARE JAMMED AT THE SAME TIME. I call it Three-Lock Migraine Failure. One key, even a perfectly cut citrate key, only opens one lock. The other two stay jammed. Which is why women try magnesium for three weeks, see a bit of gut trouble and no change, and quit. 70% of women in a Migraine Dietitian poll did exactly that. They were not wrong to try. They were given three keys' worth of problem and one key's worth of advice. THE THREE-REQUIREMENT FRAMEWORK. ONE. Block the door. Citrate. The Peikert trial dose. The only form with a positive prophylactic randomised controlled trial. TWO. Calm the nerves. Glycinate. Magnesium bonded to glycine (glycine is itself an inhibitory neurotransmitter). The form clinically used for nerve calming and sleep architecture, and the form that crosses the blood-brain barrier far more efficiently than oxide. THREE. Fuel the cells. Malate. A direct substrate for the Krebs cycle. Goes after the ATP deficit Lodi's MRI scanner saw. You need ALL THREE. AT THE RIGHT DOSE. FOR AT LEAST SIX WEEKS. Plain oxide from the chemist: one key, badly cut. Topamax: addresses none of the three locks, blunts your memory instead. Triptans: stop the attack after the door has already opened. Botox: quiets the periphery, leaves the locks alone. Aimovig: blocks a downstream signal, leaves all three locks jammed, which is why women on it describe "the miracle turned into a nightmare" in the side-effect forums. A QUICK NOTE ABOUT LINDA. I had a second patient before Patricia. Linda, 51, retail buyer, perimenopausal. Twelve attack days a month. She had refused Botox. Week three on the protocol she rang me out of hours. She said: "Doctor, I just slept SEVEN HOURS. Three nights in a row. I FORGOT WHAT THAT FELT LIKE. I am not sure I trust it. But it happened." Week ten she was at four attack days a month. She has been at four or fewer for fourteen months as of writing. I HAD BEEN ABOUT TO START FORMULATING SOMETHING WHEN I FOUND OUT IT ALREADY EXISTED. It's called NerveMag™. I did not make it. I have no equity. A small team of UK biochemists, working out of a lab in Cambridgeshire, formulated it. Three magnesium forms (citrate, glycinate, malate) at doses that map onto the published trial work. Plus 400mg of riboflavin, the exact Schoenen 1998 dose. CoQ10 at 150mg, the Gaul 2015 dose. Standardised PA-free feverfew, which has AAN Level B evidence. Deliberately no butterbur, that was withdrawn from the AHS guideline in 2015 on hepatotoxicity grounds. GMP-certified UK manufacture. Third-party tested. Two capsules a day rather than the four-pill burden of the older formulations. I started referring patients quietly. Then less quietly. THE PHONE CALLS STARTED EIGHT MONTHS IN. First came the "concerned colleague" emails. Then a former classmate who is now a senior commercial director at a CGRP-injectable manufacturer asked me, in person, over a flat white I no longer want to drink: "Marcus, do you understand what you are doing to the market with this?" I told him I understood exactly what I was doing. Then I was quietly dropped from a research consortium I had served on for four years. Then a hospital administrator I have known for a decade told me, off the record, that "questions are being asked". Then the journal correspondence I had been invited to write was politely declined. They are not coming after me because I am wrong. They are coming after me because there is a seven-billion-pound global CGRP injectable market, and an Aimovig list price north of £8,000 a year, that does not benefit from a £40 supplement working. Patricia came back at week twelve. She had had four attack days in the previous month, down from twelve. She had been off topiramate for ten weeks. She had not written the words "I AM DONE" in a notebook for forty-one days. Her words at week twelve: "I AM ANGRY. I am ANGRY. Why did nobody tell me this five years ago?" Across the cohort of women I have referred over the last two years, 73% have reported a meaningful reduction in attack days within ten weeks. NerveMag carries a 90-day empty-bottle guarantee, which I have personally verified by reading their refund page twice. I am not selling anything. I don't get a kickback. I don't have equity. I am not on their payroll. I am a clinical neurologist who is no longer willing to keep his head down. If you have tried magnesium and quit, if your bloods came back normal, if you have been told it's just your hormones, if the injectables have hurt you, read the article. It walks through every study and every trial in plain English. Dr Marcus Hartwell, Headache Mechanism Research Institute https://www.lumedly.com/nervemag/blog
